Shija Tabassum
Alladi Saritha
Abstract
The procured sample of Oxaprozin was tested for its identification. The manufacturer also was
confirmed of quality and purity of sample. The sustained release tablets of Oxaprozin were prepared
by wet granulation method, They were evaluated for weight variation, drug content, friability, hardness,
and thickness for all batches (T-1 – T-10). The release of Oxaprozin from sustained release tablet of
various formulations varied according to the ratio and degree of the polymer. In case of tablet of
T1containing drug & HPMCK15M (quantity in mg). 200: 15: the release profile, was showing the
release 102.69%. In case of tablets of T2 containing drug and HPMC K15M & HPMC K4M (in mg).
200:10:20 it was showing 100.25% release in 24 hours. In case of tablets of T3 containing drug
polymer’s (HPMCK15M, HPMCK4M in mg) 200: 15: 15: prepare to be seen in the effect of
combination of polymers in release of drug but it was showing same release given 100.25% upto 24
hour. In case of tablets T4 containing drug and HPMC K15M & HPMCK 4M (in mg) 200: 10: 10 the
release profile was showing drug release more than 100%. In case of tablets of T5 containing drug and
HPMC K 4M & HPMC K15M PVP K30 (in mg) 200: 10: 10:10. Prepared the tablets. But it cannot
maintain the release with in 100%. In case of tablets of T6 containing drug and HPMC K 15M (in Mg)
200: 5. It was seen the increase in release of drug and shown more than 100% drug release in 24 hour
profile. In case of tablets T7, containing drug. HPMCK4M & HPMCK15M (in mg) 200:10:10 the
release profile was showing drug release more than 100%. In case of Tablets T8 containing drug.
HPMCK15M (in mg) 200 : 23. The release profile was showing drug release with in 24 hours. With
very slower release than all formulations containing % drug release 99.56. Results of stability studies
of batch T-8 indicates that it was stable at 40°C/75% + 5% relative humidity as there was no significant
difference was observed for dissolution and average drug content data after two months.
Keywords: Formulation Development, Evaluation, Sustained Release, Oxaprozin.
References
1. Gambhire MN, Ambade KW, Kurmi SD, Kadam VJ, Jadhav KR. Development and in vitro
evaluation of an oral floating matrix tablet formulation of diltiazem hydrochloride. AAPS Pharm
Sci Tech. 2007;8:E73. [PMC free article] [PubMed] [Google Scholar]
2. Gordon ER, Rosanke TW, Fonner OE, Anderson NR, Baker GS. Pharmaceutical dosage forms:
Tablets. In: Lieberman HA, Lachman L, Schwartz, editors. New York: Marcel Dekker; 1990. p. 83.
[Google Scholar]
3. Vayas SP, Khar RK. 1st ed. New Delhi: Vallabh Prakashan; 2002. Controlled drug delivery
concepts and advances; p. 100. [Google Scholar]
4. Reddy KR, Mutalik S, Reddy S. Once-daily sustained release matrix tablets of nicorandil:
Formulation and in vitro valuation. AAPS Pharm Sci Tech. 2003;4:E61. [PMC free article]
[PubMed] [Google Scholar]
5. Siddique S, Mohd Y. Formulation of sustained release matrix of highly water soluble drugs. Pharma
Review. 2008 [Google Scholar]
6. King RE. Tablets in remington’s pharmaceutical sciences. In: Coy MP, editor. 15th ed. Vol. 1.
Pennsylvania: 1975. [Google Scholar]
7. Jain NK. 1st ed. Vol. 1. CBS Publishers and Distributers; 1975. Pharmaceutical Product
Development” pp. 420–21. (428–29). [Google Scholar]
8. Krishnaiah YS, Karthikeyan RS, Gouri Sankar V, Satyanarayana V. Three-layer guar gum matrix
tablet formulations for oral controlled delivery of highly soluble trimetazidine dihydrochloride. J
Control Release. 2002;81:45–56. [PubMed] [Google Scholar]
9. Subal CB, Kesevan SK, Murugesan R. Design and release characteristics of sustained release tablet
containing metformin HCl. Braz J Pharm Sci. 2008;44:477–83. [Google Scholar]
10. Rahman Z, Ali M, Khar R. Design and evaluation of bilayer floating tablets of captopril. Acta
Pharm. 2006;56:49–57. [PubMed] [Google Scholar]